Greenleaf Trust Acquires 86 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Greenleaf Trust lifted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQVGet Rating) by 2.8% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 3,119 shares of the medical research company’s stock after purchasing an additional 86 shares during the period. Greenleaf Trust’s holdings in IQVIA were worth $677,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. United Capital Financial Advisers LLC grew its holdings in shares of IQVIA by 8.4% during the 2nd quarter. United Capital Financial Advisers LLC now owns 1,850 shares of the medical research company’s stock valued at $401,000 after purchasing an additional 144 shares during the last quarter. Rhumbline Advisers grew its holdings in IQVIA by 15.7% in the 2nd quarter. Rhumbline Advisers now owns 438,629 shares of the medical research company’s stock worth $95,178,000 after acquiring an additional 59,542 shares during the last quarter. Cetera Advisor Networks LLC grew its holdings in IQVIA by 7.4% in the 2nd quarter. Cetera Advisor Networks LLC now owns 28,840 shares of the medical research company’s stock worth $6,258,000 after acquiring an additional 1,977 shares during the last quarter. Checchi Capital Advisers LLC grew its holdings in IQVIA by 17.6% in the 2nd quarter. Checchi Capital Advisers LLC now owns 1,835 shares of the medical research company’s stock worth $441,000 after acquiring an additional 275 shares during the last quarter. Finally, Bridgewater Associates LP grew its holdings in IQVIA by 14.7% in the 2nd quarter. Bridgewater Associates LP now owns 16,977 shares of the medical research company’s stock worth $3,684,000 after acquiring an additional 2,170 shares during the last quarter. Institutional investors own 86.77% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. StockNews.com assumed coverage on shares of IQVIA in a report on Wednesday, October 12th. They issued a “hold” rating on the stock. Argus raised their price target on shares of IQVIA from $260.00 to $275.00 in a report on Thursday, August 18th. Credit Suisse Group cut their target price on shares of IQVIA from $300.00 to $265.00 and set an “outperform” rating on the stock in a research note on Thursday, October 27th. Guggenheim lifted their target price on shares of IQVIA to $249.00 in a research note on Thursday, October 27th. Finally, Barclays lifted their target price on shares of IQVIA from $215.00 to $235.00 and gave the company an “overweight” rating in a research note on Thursday, October 27th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and an average price target of $257.57.

IQVIA Trading Up 0.8 %

Shares of NYSE IQV opened at $217.72 on Thursday. IQVIA Holdings Inc. has a 1 year low of $165.75 and a 1 year high of $285.61. The stock has a market cap of $40.44 billion, a P/E ratio of 35.46, a price-to-earnings-growth ratio of 2.06 and a beta of 1.37. The firm has a 50-day moving average of $196.79 and a 200 day moving average of $210.49. The company has a debt-to-equity ratio of 2.29, a current ratio of 0.90 and a quick ratio of 0.90.

About IQVIA

(Get Rating)

IQVIA Holdings, Inc engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions and real-world solutions and services to the firm’s life science clients.

Featured Stories

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.